Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

It was a landmark product -- the first fully human monoclonal antibody approved by the U.S. Food and Drug Administration -- and spent years among the world's top-selling drugs. AbbVie's sales of ...

AbbVie (NYSE:ABBV) will report Q4 2024 results ... meaning the upside to expectations comes from the existing and long-lived branded products and not because Humira is holding up better than ...